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Angiotensin II signaling and HB-EGF shedding via metallo- Angiotensin II (Ang II) has been shown to have roles
proteinase in glomerular mesangial cells. in the development of glomerulosclerosis by induction
Background. Angiotensin II (Ang II) has been implicated of hemodynamic changes and synthesis of extracellularin the development of glomerulosclerosis by stimulating fibro-
matrix proteins. Glomerular mesangial cells have abun-nectin (FN) synthesis. The processing and release of heparin
dant high-affinity Ang II receptors, which are classifiedbinding–endothelin growth factor (HB-EGF) are activated by
protein kinase C (PKC) and Ca2 signaling. We studied the pharmacologically as belonging to the Ang II type-1 re-
roles of HB-EGF and endothelial growth factor (EGF) receptor ceptor (AT1-R) subtype [1–3]. The AT1-R signal is in-
(EGFR) in Ang II-induced FN expression using mesangial cells. volved in glomerulosclerosis by stimulation of cell pro-Methods. Mesangial cells were prepared from mouse kidneys
liferation and synthesis of extracellular matrix proteinsby the explant method and cells were used at passages 4 and 5.
[4, 5]. AT1-R stimulation initiates early biochemicalResults. Ang II stimulated FN mRNA levels dose-depen-
dently with a maximal increase (3.4-fold) after 12 hours of events, including rapid production of diacylglycerol and
incubation. This action was completely inhibited by PKC inhib- inositol 1,4,5-trisphosphate by phospholipase C (PLC)-
itors and slightly blocked by Ca2 chelating agents. FN mRNA mediated hydrolysis of inositol phospholipids and activa-accumulation by Ang II was abolished by tyrosine kinase inhib-
tion of protein kinase C (PKC) [6–9]. Ang II also inducesitors, a specific inhibitor for EGFR (AG1478) and extracellular
signal-regulated kinase (ERK) inactivation. Addition of neu- a rapid increase in expression of growth-associated nu-
tralizing anti–HB-EGF antibody, as well as pretreatment with clear proto-oncogenes as observed in cellular events me-
heparin or the metalloproteinase inhibitor batimastat abol- diated by peptide growth factors, and stimulates tyrosine
ished induction of FN expression by Ang II. In mesangial cells
phosphorylation of multiple substrates, including extra-stably transfected with a chimeric construct containing HB-
cellular signal-regulated kinases (ERK) [10–15].EGF and alkaline phosphatase (ALP) genes, ALP activity in
incubation medium was rapidly increased by Ang II (1.7-fold Signaling through ERK in response to various G pro-
at 0.5 min) and reached a 4.1-fold increase at two minutes. tein-coupled receptor agonists has been shown to rely
Ang II phosphorylated EGFR (maximal at 2 min) and ERK on transactivation of the EGFR [reviewed in 16, 17].(maximal at 8 min) in a PKC- and metalloproteinase-depen-
Daub et al originally found the role of EGFR-mediateddent manner. Ang II stimulated the expression and release of
transforming growth factor- (TGF-) via EGFR-mediated signaling in Ras/ERK activation by G-protein-coupled
signaling, and the released TGF- also contributed to Ang II- receptors (GPCRs) [18]. Ang II also was found to trans-
mediated FN expression via EGFR transactivation. activate EGFR in cardiac fibroblasts or vascular smooth
Conclusions. Ang II-mediated FN expression was regulated
muscle cells (VSMC) [19–23]. EGFR transactivation wasby autocrine effects of HB-EGF and TGF-, suggesting a novel
initially suggested to be independent of EGFR ligands,paradigm for cross-talk between Ang II and growth factor
receptor signaling pathways. based on the rapid onset of EGFR tyrosine phosphoryla-
tion and the failure to detect EGFR ligands, in particular
EGF, in conditioned medium of stimulated cells [18, 19,Key words: angiotensin II, HB-EGF, TGF-, fibronectin, mesangial
cell, EGF receptor, cell signaling. 21]. Thereafter, several groups reported the involvement
of HB-EGF in GPCR-mediated EGFR transactivationReceived for publication February 6, 2001
[24–26]. Filardo et al demonstrated that estrogen alsoand in revised form July 23, 2001
Accepted for publication July 25, 2001 activated ERK via HB-EGF-mediated EGFR activation
[27]. HB-EGF is a heparin-binding member of the EGF 2001 by the International Society of Nephrology
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family and is synthesized as a transmembrane precursor glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
that is then proteolytically processed into the mature, as an internal control. Signals were measured by scanning
soluble growth factor. This proteolytic processing was densitometry, and FN mRNA levels were normalized
reported to be regulated by PKC and Ca2 signaling [28]. relative to the GAPDH mRNA levels. Ca2 levels were
Although accumulating evidence suggested the involve- measured using fura-2/AM as reported [20].
ment of HB-EGF in EGFR transactivation, the actual We constructed a pRC expression vector containing
release of HB-EGF into incubation medium has not been the human alkaline phosphatase (ALP) cDNA subcloned
demonstrated, and it remains undefined whether such a between human HB-EGF signal sequence and the cod-
signaling mechanism is operating in mesangial cells. ing region for mature human HB-EGF protein (pALP-
Fibronectin (FN) is an extracellular matrix and plasma HB-EGF) [33]. This pAlp-HB-EGF (30 g) was trans-
protein with various functions that plays important roles fected into mesangial cells using LIPOFECTAMINE
in mesangial cells, cell adhesion and migration [29]. This PLUS (Gibco BRL) and selected with G418 [19, 20].
study focused on the signaling mechanism for Ang II- Three stable cell lines with high ALP activity in the
induced FN expression in mesangial cells, and examined incubation medium were selected and analyzed in this
whether Ang II actually stimulates the processing and experiment. For determination of ALP activity, the incu-
release of HB-EGF, which in turn transactivates the bation medium was heated at 70C for ten minutes and
EGFR-mediated ERK pathway to regulate FN gene ex- aliquots of 100 L were further incubated at 37C for
pression in mesangial cells. five minutes in assay buffer (100 L) containing dietha-
nolamine (2 mol/L, pH 9.8), MgCl2 (2 mmol/L), homo-
arginine (0.4 mol/L) and disodium p-nitrophenyl phos-METHODS
phate (12.5 mmol/L). The sample volume was expandedMaterials
to 1 mL and absorbance at 405 nm was read. The values
Heparin binding-EGF, genistein, AG1478, AG1295, were normalized with cellular protein using bovine serum
herbimycin, BAPTA-AM, PD98059 and TMB-8 were albumin (BSA) as a standard (Pierce Chemical, Rockford,
purchased from Calbiochem (La Jolla, CA, USA). Stau- IL, USA) and background absorbance in the medium,
rosporin, calphostin-C, phorbol 12-myristate 13-acetate and are shown relative to the time 0 control value.
(PMA) and heparin (porcine intestinal mucosa) were
from Sigma (St. Louis, MO, USA). Angiotensin II and Measurement of ERK and EGFR phosphorylation
EGF were from Peptide Institute Inc. (Osaka, Japan)
Tyrosine-phosphorylation of EGFR was analyzed inand Toyobo (Osaka, Japan), respectively. Antibodies were
cells exposed to Ang II for two minutes as previouslyfrom the following vendors: Telios Pharm (FN), Santa
described [19, 20]. After brief sonication, samples wereCruz Biotechnology (Santa Cruz, CA, USA; EGFR, HB-
incubated for 30 minutes at 4C, centrifuged for fiveEGF, normal rabbit IgG), New England Bio-Labs (Bev-
minutes at 15,000 g and the supernatant was incubatederly, MA, USA; phospho-specific ERK), Upstate Bio-
with anti-rabbit EGFR antibody for 16 hours at 4C.technology (Lake Placid, NY, USA; phospho-tyrosine
Immune complexes were affinity-purified by anti-rabbit4G10), R&D Systems (Wiesbaden, Germany; pan-selec-
IgG agarose beads (Sigma), transferred on nitrocellulosetive TGF-). The metalloproteinase inhibitor batimastat
membranes, blotted with anti-phosphotyrosine antibodywas from British Biotech (Cowley, Oxford, UK). The
and detected with the enhanced chemiluminescence kitAT1-R antagonist RNH6270 (active form of CS866) was
(Amersham Japan, Tokyo, Japan). Threonine/tyrosine-provided by Sankyo Co. Ltd (Tokyo, Japan).
phosphorylation of ERK was determined in cells ex-
posed to Ang II for eight minutes using phospho-ERKCell culture
antibody [19, 20].Mesangial cells were prepared from kidneys of 8-week-
old male C57BL/6 mice by the explant method [3], and
Detection of FN released into mediumcultured with Dulbecco’s modified Eagle’s medium
Quantification of FN secreted into medium was per-(DMEM) containing 10% fetal calf serum (FCS). Sub-
formed as previously reported [22]. Following 12 hoursconfluent cells (passages 4 and 5) were serum-starved for
of incubation of cells with or without Ang II (100 nmol/L),24 hours and then used for the experiments.
100 Ci/ml of [35S]-methionine was added for further 12
Northern blotting, stable transfection of DNA, hours. Aliquots of the medium were incubated with rab-
Ca2 analyses and measurement of ALP activity bit anti-FN antibody for 16 hours at 4C. Immune com-
plexes were affinity-purified using protein A-sepharoseTotal RNA was extracted using TRIZOL Reagent
beads and analyzed by sodium dodecyl sulfate-polyacryl-(Gibco BRL, Paisley, Scotland, UK), fractionated on 1%
amide gel electrophoresis (SDS-PAGE). The intensityagarose/formaldehyde gels, and transferred onto nylon
of signals of 220 kD was determined by densitometry andmembranes [30–32]. Blots were then hybridized with
random-primed 32P-labeled cDNA probes for FN and the value in the control was arbitrarily expressed as 1 unit.
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Binding assay and measurement of TGF- tained a similar level until 24 hours (data not shown).
Mesangial cells expressed only AT1-R (kD  0.61 Membrane preparation and binding assay were per-
0.02 nmol/L, Bmax  1.55  0.14 pmol/mg protein), andformed as previously described [34–36]. Briefly, cells
AT2-R was not detectable in these cells (N 4; Fig. 1B).were homogenized in ice-cold PBS containing protease in-
Subsequent experiments were performed with 100 nmol/Lhibitors [1 g/mL phenylmethylsulfonyl fluoride (PMSF),
Ang II stimulation for 12 hours.1 g/mL leupeptin, 0.2% (wt/vol) aprotinin, 1 g/mL
antipain] and centrifuged at 1000 g for ten minutes. The Phorbol ester-sensitive PKC rather than Ca2 is
supernatants were further centrifuged at 48000 g for 30 involved in Ang II-induced FN mRNA accumulation
minutes. The resulting pellet was resuspended in assay To address the role of PKC in AT1-R signaling,
buffer containing 50 mmol/L Tris (pH 7.6), 100 mmol/L cells were treated with the PKC inhibitors staurosporin
NaCl, 10 mmol/L MgCl2, 1 mmol/L egtazic acid (EGTA), (40 nmol/L) or calphostin-C (50 nmol/L). These inhibi-
0.25 mg/mL BSA and protease inhibitors. Protein con- tors interacted with the adenosine 5-triphosphate (ATP)
tent was determined using a BCA Protein Assay Kit binding site and regulatory subunit of PKC, respectively
(Pierce) with BSA as a standard. Membrane fractions [37, 38], and were found to completely inhibit AT1-R-
(50 g of protein) were incubated with 125I-[Sar1, Ile8] mediated FN mRNA accumulation (Fig. 2A). Phorbol
Ang II for the saturation experiment (0.1 to 5 nmol/L) ester (PMA, 100 nmol/L) also markedly up-regulated
in a total assay volume of 300 L for 90 minutes at 21C. FN mRNA levels. Ang II-mediated FN mRNA accumu-
lation was partially inhibited by pretreatment withSpecific 125I-[Sar1, Ile8] Ang II binding was determined
BAPTA-AM (12.5 mol/L) and TMB8 (100 mol/L),from the difference between counts in the absence and
commonly used as intracellular Ca2 chelators, (68%presence of 3 mol/L unlabeled Ang II. Total Ang II
and71%, respectively, vs. FN mRNA level in the pres-receptor numbers (Bmax) and kD values were determined
ence of Ang II), whereas EGTA had no effect on theby Scatchard analysis, and AT1-R and AT2-R were sepa-
induction (Fig. 2A). These concentrations of Ca2 chela-rately calculated from total Ang II receptor numbers on
tors were sufficient to abolish Ang II-induced intracellu-the basis of distribution ratio determined by nonlinear
lar Ca2 mobilization (Fig. 2B). These results suggestedleast-squares regression analysis by inhibition with losar-
that PKC-mediated pathways rather than Ca2 signalingtan or CGP42112A using the GraphPad InPlot computer
play a dominant role in Ang II-induced FN mRNA accu-program (Graph Pad, San Diego, CA, USA) [34].
mulation in mesangial cells.To measure the amounts of TGF-1 protein in the
conditioned culture medium, we used an enzyme-linked Induction of FN mRNA by Ang II is regulated by
immunosorbent assay (ELISA) kit (R&D Systems) ac- EGFR-mediated ERK signaling
cording to the manufacturer’s instructions. Cells were To examine whether tyrosine kinases and EGFR trans-
incubated in serum-free medium for 12 hours and then activation are involved in Ang II-induced FN expression,
stimulated with Ang II (100 nmol/L) for 12 hours. Ali- cells were pretreated with genistein 200 mol/L or herbi-
quots of medium were obtained and the assay was re- mycin 1 mol/L with a strong preference for tyrosine-
peated three times. specific kinases [39]. These inhibitors markedly inhibited
Ang II-induced FN mRNA accumulation (Fig. 3A) with
Statistical analysis no effects on basal FN mRNA levels (data not shown). A
specific inhibitor of EGFR (AG1478, 1 mol/L) [19] andThe results are expressed as means  SE. Statistical
ERK inactivation by the MEK inhibitor PD98059 abol-analysis was performed by one-way ANOVA followed
ished Ang II-induced FN mRNA accumulation, althoughby pair-wise contrasts using the Dunnett multiple com-
the platelet-derived growth factor receptor (PDGFR)parison test. Data were considered statistically significant
inhibitor AG1295 had no effect (Fig. 3A). The specificitywhen P was 	0.05.
of AG1478 as an inhibitor for EGFR phosphorylation
was well established in our previous studies by testing
RESULTS the effects of a dominant negative mutant of EGFR [19].
EGF stimulated FN mRNA levels, and this increase wasAng II-induced FN mRNA level is mediated by
blocked by AG1478 and PD98059 (Fig. 3B). The phorbolAT1-R stimulation
ester also up-regulated FN expression, which was abol-
Angiotensin II dose-dependently induced FN mRNA ished by AG1478 and PD98059.
accumulation with an EC50 of45 nmol/L and a maximal
HB-EGF is processed and released by Ang IIpeak at 100 nmol/L, which were completely blocked by
signaling to up-regulate FN expressionthe AT1-R antagonist RNH6270 (1 mol/L; Fig. 1A).
Ang II (100 nmol/L) significantly stimulated FN mRNA We next tested whether HB-EGF is actually released
accumulation after six hours of incubation, reaching a via proteolytic processing by metalloproteinase after the
addition of Ang II to regulate FN expression. Figure 4Amaximal increase after 12 hours and thereafter main-
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Fig. 1. Dose-dependent effects of angiotensin II (Ang II) on fibronectin (FN) mRNA accumulation and characterization of Ang II receptors in
mesangial cells. (A) Mesangial cells were stimulated by Ang II at the indicated concentrations for 12 hours. Total RNA (15 g) was separated
on agarose formaldehyde gels and transferred onto nylon membranes for hybridization with 32P-labeled FN or GAPDH cDNA probes. Densities
of FN mRNA signals were measured by densitometry and normalized relative to those of GAPDH mRNA signals. The results are arbitrarily
indicated as values relative to FN mRNA levels in the unstimulated cells (control). Results shown are means  SE of four separate experiments
and representative data are shown. *P 	 0.01 vs. the control. RNH is AT1-R antagonist (1 mol/L). (B) Saturation curve and Scatchard plots for
membrane fractions from mesangial cells. Membrane preparation and binding assay were performed as described in the Methods section. B/F
means the molar ratio of bound I125–Ang II to free I125-Ang II. Symbols are: () total; () non-specific; () specific.
shows that addition of neutralizing anti-HB-EGF anti- ated by measuring ALP activities in the incubation medium
(Fig. 4B). ALP activity was rapidly increased after addi-body, heparin (which competes with cell surface-associ-
ated heparan sulfate proteoglycans as coreceptors for tion of Ang II (1.7-fold at 0.5 min) and reached a 4.1-fold
increase at two minutes. Pretreatment with calphostin-CHB-EGF binding to EGFR) [40], and the metalloprotei-
nase inhibitor batimastat completely inhibited Ang II- or batimastat completely abolished the Ang II-mediated
increase in ALP activity. Pretreatment with BAPTA-mediated FN mRNA accumulation. Batimastat has a
collagen-mimicking hydroxamate’s structure, which fa- AM tended to reduce the induction of ALP activity by
Ang II, while AG1478 had no effect. Similar results werecilitates chelation of the zinc ion in the active site of
membrane-bound zinc-endopeptidases, metalloprotei- obtained in three different clones, indicating that Ang II
rapidly induces the proteolytic processing of pro-HB-nases (MMPs), including the interstitial collagenases,
stromelysins 1-3, matrilysin, 92 kD gelatinase B (MMP-9), EGF via metalloproteinases in a PKC-dependent man-
ner to stimulate the maturation and release of HB-EGF.and the 72 kD gelatinase A (MMP-2) [41]. HB-EGF also
stimulated FN expression, which was blocked by heparin
Ang II transphosphorylates EGFR to activate ERKand neutralizing anti-HB-EGF antibody. FN induction
by PMA was abolished by pretreatment with 
HB-EGF Next, we tested whether Ang II actually tyrosine-phos-
phorylates EGFR and activates ERK. Tyrosine-phosphor-and batimastat, indicating that PKC is located upstream
of proHB-EGF processing in the Ang II signaling pathway. ylation of EGFR was maximally activated two minutes
after addition of Ang II, and was completely abolished byTo define the mechanism of HB-EGF processing by
Ang II further, we established mesangial cells stably trans- addition of calphostin-C, heparin, batimastat, or AG1478
(Fig. 5A). ERK activation was examined using an anti-fected with an expression vector containing ALP cDNA
between the HB-EGF signal sequence and HB-EGF phospho-ERK antibody. ERK activation was maximally
activated eight minutes after addition of Ang II. In accor-cDNA. The processing and release of HB-EGF were evalu-
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Fig. 2. Effects of protein kinase C (PKC) and Ca2 signals on Ang II-induced FN mRNA levels. (A) Mesangial cells were pretreated with or
without the PKC inhibitor staurosporin (40 nmol/L), calphostin-C (50 nmol/L), intracellular Ca2 chelator BAPTA-AM (12.5 mol/L), TMB-8
(100 mol/L) or extracellular Ca2 chelator EGTA (5 mmol/L) for 30 minutes, and then stimulated with Ang II (100 nmol/L) or PMA (100 nmol/L)
for 12 hours. Quantification of mRNA levels was performed as described in Fig. 1. Results shown are means  SE of four separate experiments
and representative data are shown. *P 	 0.01 vs. the control. (B) Mesangial cells were incubated in the presence of fura 2-AM and stimulated
with Ang II (100 nmol/L). Traces are typical of those from three separate experiments. Intracellular Ca2 levels were expressed in nmol/L.
dance with the results regarding EGFR phosphorylation, with AG1478 or PD98059 completely abolished Ang II-
induced FN secretion (Fig. 5C).Ang II-mediated ERK activation was abolished by pre-
treatment with PKC inhibitors, heparin, batimastat or
Ang II stimulates TGF- mRNA accumulation andAG1478 (Fig. 5B).
secretion leading to induction of FN
Ang II-induced FN mRNA expression results in an Angiotensin II has been shown to induce TGF- ex-
increase in FN protein release pression in mesangial cells [4]. However, it remains to
be determined whether HB-EGF-mediated EGFR acti-To examine whether FN mRNA accumulation results
in an increase in FN protein level, FN protein secreted vation is involved in TGF- expression. Figure 6A shows
that Ang II up-regulated TGF- mRNA expression byinto the medium was analyzed by immunoprecipitation
using anti-FN antibody. Immunoprecipitated FN secreted 1.8-fold, which was abolished by PKC inhibitors, heparin,
batimastat, AG1478 and PD98059, indicating the involve-into medium was increased by 2- and 2.8-fold over the
control by Ang II and EGF, respectively. Pretreatment ment of the HB-EGF-EGFR-ERK pathway in Ang II-
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Fig. 3. Effects of tyrosine kinase inhibitors
and epidermal growth factor receptor (EGFR)
antagonist on Ang II-induced FN mRNA accu-
mulation. Mesangial cells were pretreated with
or without the tyrosine kinase inhibitors gen-
istein (200mol/L), herbimysin (1mol/L), spe-
cific inhibitors of EGFR (AG1478, 1 mol/L)
or PDGF (AG1295, 1 mol/L), MEK inhibi-
tor PD98059 (10 mol/L) for 30 minutes and
then challenged with Ang II (100 nmol/L),
EGF (10 ng/mL) or PMA (100 nmol/L) for
12 horus. Quantification of mRNA levels was
performed as described in Fig. 1. Results
shown are means SE of four separate exper-
iments and representative data are shown.
*P 	 0.01 vs. the control.
mediated TGF- mRNA expression. The TGF-1 con- To determine the contribution of released TGF- to
Ang II-mediated FN expression, we found that the addi-centrations in the incubation medium were measured.
As shown in the right panel of Figure 6A, the mean tion of neutralizing anti-TGF- antibody partially inhib-
ited Ang II-mediated FN expression (61% vs. FNamount of active TGF-1 present in six control cell cul-
tures was 0.13 ng/mL. When stimulated with 100 nmol/L mRNA level in the presence of Ang II), while this con-
centration of anti-TGF- antibody completely blockedAng II, a 3.2-fold increase to 0.42 ng/mL was observed.
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Fig. 4. Metalloproteinase cleavage of pro-
HB-EGF is involved in Ang II-induced FN
mRNA accumulation. (A) Cells were pre-
treated for 30 minutes with neutralizing anti-
HB-EGF antibody (
HB-EGF, 1 g/mL),
heparin (100 g/mL) and the metallopro-
teinase inhibitor batimastat (10 mol/L), and
then stimulated with Ang II (100 nmol/L),
HB-EGF (20 ng/mL) or PMA (100 nmol/L)
for 12 hours. Quantification of mRNA levels
was performed as described in Fig. 1. (B) Cells
stably transfected with pALP-HB-EGF were
stimulated for two minutes with Ang II (100
nmol/L) with or without calphostin-C (50
nmol/L), batimastat (10 mol/L), AG1478 (1
mol/L) or BAPTA-AM (10 mol/L). ALP
activity in the incubation medium was deter-
mined as described in the Methods section.
The ALP activities (N 4 in each experiment)
are shown relative to the values of 0 time
control arbitrarily given a value of 1. Results
shown are means SE of four separate exper-
iments and representative data are shown.
*P 	 0.01 vs. the control.
TGF- (1 ng/mL)-mediated FN expression (Fig. 6B). manner rather than PKC signals in cardiac fibroblasts
[19, 20] or VSMC [21]. Daub et al originally found theWe also studied whether the released TGF- can phos-
role of EGFR-mediated signaling in Ras/ERK activationphorylate EGFR to activate ERK. As shown in Figure
by G-protein-coupled receptors (GPCRs) [18] and there-6C, TGF- (1 ng/mL) has the ability to activate EGFR
after several groups reported the involvement of HB-and ERK, and pretreatment with AG1478 abolished this
EGF in GPCR-mediated EGFR transactivation [24–26].action, suggesting that TGF- released by Ang II signal-
Filardo et al demonstrated that estrogen also activateding also contributes to the induction of FN protein by
ERK via this HB-EGF-mediated EGFR activation [27].activating the EGFR-ERK pathway.
However, the actual release of HB-EGF into the incuba-
tion medium was not demonstrated in these previous
DISCUSSION studies, and it remains to be determined whether such
Fibronectin plays an important role in extracellular a signaling mechanism is operating in the mesangial cells.
matrix accumulation secondary to glomerulosclerosis [29]. The major new findings of the present study are that
Ang II induced the synthesis and secretion of FN and (1) the processing and release of HB-EGF are actually
collagen types I and III from mesangial cells [2, 4]. Recent caused by AT1-R-mediated PKC signaling in a metallo-
evidence demonstrated that Ang II-induced ERK activa- proteinase-dependent manner; (2) the released HB-EGF
tion was mainly mediated via downstream signaling of binds to EGFR, which transactivates EGFR-mediated
ERK pathway to up-regulate FN expression; (3) EGFREGFR transactivated by AT1-R in a Ca2-dependent
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Fig. 5. Ang II-mediated tyrosine-phosphory-
lation of EGFR and ERK and secretion of
FN protein. Cells were pretreated as described
in Fig. 4, and then stimulated with Ang II (100
nmol/L) for two minutes (EGFR phosphory-
lation) and for eight minutes (ERK activa-
tion). (A) Cellular extracts were immunopre-
cipitated with anti-EGFR antibody and then
blotted with anti-phosphotyrosine antibody
(
PY). The same filters were reprobed with
anti-EGFR antibody. (B) Cellular extracts
were blotted with anti-phospho ERK antibody
to detect ERK phosphorylation. The same fil-
ters were reprobed with anti-ERK antibody.
(C) Cells were pretreated with or without
AG1478 (1 mol/L), PD98059 (10 mol/L)
for 30 minutes, and then exposed to Ang II
(100 nmol/L) or EGF (10 ng/mL) for 12 hours.
Cells were subsequently incubated with [35S]-
methionine for a further 12 hours. Culture
supernatants were used for FN immunopre-
cipitation as described in the Methods section.
Signals of 220 kD representing FN were mea-
sured by densitometry, and the value in the
control was arbitrarily expressed as 1 unit.
Values represent means  SE of three sepa-
rate experiments. *P 	 0.01 vs controls (un-
stimulated cells).
transactivation plays a key role in transmitting Ang II leased TGF- activates the EGFR-ERK pathway and
partially contributes to Ang II-mediated FN expression.signals to ERK activation in mesangial cells; (4) induc-
tion of TGF- synthesis by Ang II is also regulated by The present findings demonstrated that ERK activa-
tion plays a key role in Ang II-induced FN expression.this EGFR-mediated ERK signaling; and (5) the re-
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Fig. 6. Ang II-induced TGF- expression and release, and role of released TGF- in Ang II-mediated FN expression and EGFR activation by
TGF-. (A) Cells were pretreated for 30 minutes with staurosporin (40 nmol/L), calphostin-C (50 nmol/L), heparin (100 g/mL), batimastat (10
mol/L), AG1478 (1 mol/L) or PD98059 (10 mol/L), and then stimulated with Ang II (100 nmol/L) for 12 hours. Quantification of TGF-
mRNA levels was performed as described in Fig. 1. In the right panel, active TGF-1 concentrations in the incubation medium were measured
by ELISA. Cells were incubated in serum-free medium for 12 hours (control) and then stimulated with Ang II (100 nmol/L) for 12 hours (Ang
II). Results are means  SE of six independent experiments. (B) Cells were incubated for 12 hours with Ang II (100 nmol/L) in the presence of
neutralizing rabbit anti-TGF- antibody (10 ng/mL) or anti-rabbit IgG (100 ng/mL). FN mRNA levels were quantified by Northern blotting as
described in Fig. 1. Values represent means  SE of four separate experiments. **P 	 0.01 vs. controls, *P 	 0.05 vs. Ang II-stimulated cells.
(C) Cells were stimulated with TGF-1 (1 ng/mL) for two minutes (EGFR phosphorylation) or for eight minutes (ERK activation), and EGFR
phosphorylation was determined as described in Fig. 5. AG1478 (1 mol/L) was added 30 minutes before addition of TGF-1.
ERK was shown to be phosphorylated downstream of late FN expression in mesangial cells. EGFR transactiva-
tion by Ang II was shown to be regulated by Ca2 signal-EGFR activated by Ang II in cardiac fibroblasts [19, 20]
or VSMC [21, 26]. This study extended the previous ing rather than the PKC pathway in cardiac fibroblasts
[19, 20] or VSMC [21, 23]. Although at present we cannotobservations, and clearly showed that PKC signaling
mainly transactivates the EGFR/ERK pathway to stimu- explain the differential regulation in Ang II-mediated
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EGFR activation between mesangial cells, fibroblasts TGF- as well as whether HB-EGF plays a role in TGF-
and VSMC, it may be partially due to cell-type depen- signaling are necessary.
dent differences in expression of PKC isoforms or MMP In summary, we demonstrate that PKC signals acti-
isoforms. Further studies are needed to clarify this cell- vated via AT1-R played a critical role in the processing
type specific regulation in Ang II-mediated EGFR acti- and release of HB-EGF in mesangial cells, and that the
vation signal. released HB-EGF was an intervening molecule to trans-
We found that processing of HB-EGF by Ang II was mit AT1-R signals to EGFR transactivation. Furthermore,
rapidly induced (0.5 min) before maximal activation of we showed that Ang II stimulated the expression and
EGFR (2 min), and that the transactivation mechanism release of TGF- via EGFR-mediated ERK signaling,
of EGFR was mostly mediated by HB-EGF processed and that the released TGF- activates the EGFR-ERK
and released via MMPs. HB-EGF is a heparin-binding pathway and partially contributes to Ang II-mediated FN
member of the EGF family and is synthesized as a trans- expression. Thus, Ang II-mediated FN expression is reg-
membrane precursor that is then proteolytically pro- ulated by autocrine effects of HB-EGF and TGF-, sug-
cessed into the mature, soluble growth factor, and its gesting a novel paradigm for cross-talk between Ang II
proteolytic processing was reported to be regulated by and growth factor receptor signaling pathways.
MMPs in a PKC- and Ca2 -dependent manner [28],
consistent with the present observations. Estrogen-medi- ACKNOWLEDGMENTS
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